ProCE Banner Activity

How Can We Destigmatize a Hepatitis B Diagnosis? Conversations Between Patient and Physician #2

Podcast Episodes
In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B.

Released: February 24, 2022

Expiration: February 23, 2023

No longer available for credit.

Share

Faculty

Jacki Chen

Jacki Chen, PhD

Patient Advocate

Robert G. Gish

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead Sciences, Inc.

Partners

ALF

ProCE Banner

Faculty Disclosure

Primary Author

Jacki Chen, PhD

Patient Advocate

Jacki Chen, PhD, has disclosed that he has received consulting fees from GlaxoSmithKline.

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimmune, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Topography Health, Venatorx, and Viking; has served on advisory boards for Abbott, AbbVie, Altimunne, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Venatorx, and Viking; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect.